Bharat Biotech permitted to do Phase-3 trials of its intranasal Covid vaccine
Bharat Biotech, the maker of COVAXIN Covid-19 vaccine, has received regulatory approval to conduct the phase-3 clinical trials of its intranasal Covid vaccine. The vaccine is being tested for the booster dose for people who have already been administered two doses of COVAXIN. The trial will also compare the immunogenicity and safety profiles of the intranasal vaccine with COVAXIN.